ELOQUENT-1: A phase III, randomized, open-label trial of lenalidomide/dexamethasone with or without elotuzumab in subjects with previously untreated multiple myeloma (CA204-006).
暂无分享,去创建一个
M. Dimopoulos | S. Lonial | P. Richardson | D. Reece | R. Orlowski | P. Moreau | T. Facon | J. San-Miguel | A. Singhal | A. Palumbo | R. Shazer | J. Kopit | K. Anderson